References
- Hachinski V. Hypertension in acute ischaemic strokes. Arch. Neurol.42, 1002 (1985).
- Sandset EC, Bath PM, Boysen G et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled double-blind trial. Lancet377(9767), 741–750 (2011).
- Schrader J, Luders S, Kulchewski A et al. The ACCESS Study. Evaluation of acute candesartan therapy in stroke survivors. Stroke34, 1699–1703 (2003).
- Nazir FS, Overell JR, Bolster A, Hilditch TE, Reid JL, Lees KR. The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. J. Hypertens.22(5), 989–995 (2004).
- Lisk DR, Grotta JC, Lamki LM et al. Should hypertension be treated after acute stroke? A randomised controlled trial using single photon emission computed tomography. Arch. Neurol.50, 855–862 (1993).
- Nazir FS, Overell JR, Bolster A, Hilditch TE, Lees KR. Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial. Cerebrovasc. Dis.19(2), 77–83 (2005).
- Potter JF, Robinson TG, Ford GA et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol.8(1), 48–56 (2009).
- Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T; INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc. Dis.4, 204–210 (1994).
- Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose β blockade in acute stroke (‘BEST’ trial): an evaluation. Br. Med. J.296, 737–741 (1988).
- Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PM. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension47, 1209–1215 (2006).
- Sare GM, Gray LJ, Bath PMW. Effect of antihypertensive agents on cerebral blood flow and flow velocity in acute ischaemic stroke: systematic review of controlled studies. J. Hypertension26, 1058–1064 (2008).
- Yusuf S TK, Anderson C, Pogue J et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet372(9644), 1174–1183 (2008).
- Yusuf S, Diener H-C, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359(12), 1225–1237 (2008).
- Bath PM, Martin RH, Palesch Y et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke40(11), 3541–3546 (2009).
- Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
- The Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical re-analysis of functional outcomes in stroke trials. Stroke38, 1911–1915 (2007).
- Hankey GJ. Lowering blood pressure in acute stroke: the SCAST trial. Lancet377(9767), 696–698 (2011).
- The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int. J. Stroke1, 245–249 (2006).
- Anderson CS, Huang Y, Wang JG et al. Intensive blood pressure reduction in actue cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol.7, 391–399 (2008).
- Qureshi AI, Palesch YY. Antihypertensive treatment of acute cerebral hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit. Care DOI: 10.1007/s12028-011-9538-3 (2011) (Epub ahead of print).